Current Atherosclerosis Reports

Papers
(The H4-Index of Current Atherosclerosis Reports is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Revascularization Options for Left Main Disease: What Clinicians Need to Know151
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions136
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management113
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?110
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes93
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis76
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment76
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management75
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease69
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?66
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments65
The Effects of FABP4 on Cardiovascular Disease in the Aging Population64
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice61
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart57
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women53
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond50
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators49
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event42
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis41
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?40
Inflammation in the Peri-ACS Period: Ready for Prime Time?40
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?38
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?38
The Emerging Specialty of Cardio-Rheumatology37
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review36
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease35
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention33
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease33
Percutaneous Coronary Interventions in Women31
Myeloid Cells in Abdominal Aortic Aneurysm31
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women31
0.16387796401978